What is the 13F Pro Quality Score for INMB?

13F Pro ranks Inmune Bio, Inc. (INMB) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View INMB's current score at https://13fpro.ai/company/INMB (free sign-up required for the full ranking).

Which hedge funds own the most INMB stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of INMB include VANGUARD CAPITAL MANAGEMENT, AQR CAPITAL MANAGEMENT, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/INMB as soon as new 13F filings post.

Where does 13F Pro source INMB data?

All Inmune Bio, Inc. fundamentals and ownership data come directly from SEC EDGAR. Inmune Bio, Inc. files with the SEC under CIK 1711754. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is INMB in?

Inmune Bio, Inc. (INMB) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is INMB research updated on 13F Pro?

INMB's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Inmune Bio, Inc.(INMB)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1711754 INMB stock profile & AI dashboard →

13F Pro Quality Score

9.7/100

Rank #2,913 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why INMB Scores 10/100

exact factor attribution · 2026-09-11

INMB's composite is driven by earnings growth, held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

+2.2 pts

95th pct

Institutional flow

-2.1 pts

9th pct

Earnings quality

-2.3 pts

27th pct

Shareholder dilution

-2.5 pts

0th pct

Capital efficiency

-4.2 pts

8th pct

Profitability

-7.4 pts

1th pct

Free cash flow

-7.4 pts

1th pct

Scale

-7.4 pts

0th pct

Revenue growth

-9.2 pts

4th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

INMB Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Inmune Bio, Inc. (INMB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INMB at 9.7/100 on a 32-signal composite quality model, placing it at rank #2,913 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of INMB by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, AQR CAPITAL MANAGEMENT, BlackRock, based on the most recent SEC filings. INMB trades on the Nasdaq exchange and files with the SEC under CIK 1711754. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INMB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Inmune Bio, Inc. directly from SEC EDGAR. Inmune Bio, Inc.'s 13F Pro composite quality score has ranged between 10 and 26 since 2026, currently 9.7 — a declining long-term trajectory across 8 quarterly and live scoring snapshots.

Net Income

Q2 2026

$-1.3M

ROIC

Q2 2026

-29.0%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+257.1% YoY

$50.0KFY 2025

FY22 $374.0KFY23 $155.0KFY24 $14.0KFY25 $50.0K

Net Income

-9.2% YoY

$-45.9MFY 2025

FY22 $-27.3MFY23 $-30.0MFY24 $-42.1MFY25 $-45.9M

Operating Income

-11.1% YoY

$-47.4MFY 2025

FY22 $-26.0MFY23 $-29.7MFY24 $-42.6MFY25 $-47.4M

EPS (Diluted)

+11.8% YoY

$-1.86FY 2025

FY22 $-1.52FY23 $-1.67FY24 $-2.11FY25 $-1.86

Total Assets

-18.2% YoY

$32.4MFY 2025

FY22 $81.8MFY23 $57.0MFY24 $39.6MFY25 $32.4M

Total Debt

—FY 2025

FY22 $20.5MFY23 $9.9MFY24 $15.0MFY25 —

Op. Cash Flow

+32.3% YoY

$-22.6MFY 2025

FY22 $-22.7MFY23 $-12.0MFY24 $-33.4MFY25 $-22.6M

Free Cash Flow

$-23.6MFY 2025

FY22 —FY23 —FY24 —FY25 $-23.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$50.0K +257.1%	$14.0K -91.0%	$155.0K -58.6%	$374.0K +106.6%	$181.0K +1545.5%	$11.0K
Net Income	$-45.9M -9.2%	$-42.1M -40.2%	$-30.0M -9.9%	$-27.3M +10.0%	$-30.3M -150.8%	$-12.1M
Operating Income	$-47.4M -11.1%	$-42.6M -43.4%	$-29.7M -14.6%	$-26.0M +11.0%	$-29.2M -138.4%	$-12.2M
EPS (Diluted)	$-1.86 +11.8%	$-2.11 -26.3%	$-1.67 -9.9%	$-1.52 +19.1%	$-1.88	—
Total Assets	$32.4M -18.2%	$39.6M -30.6%	$57.0M -30.3%	$81.8M -18.2%	$99.9M +145.8%	$40.7M
Total Debt	—	$15.0M +51.2%	$9.9M -51.7%	$20.5M +30.7%	$15.7M +9715.0%	$160.0K
Operating Cash Flow	$-22.6M +32.3%	$-33.4M -178.5%	$-12.0M +47.2%	$-22.7M +20.4%	$-28.5M -218.7%	$-8.9M
Free Cash Flow	$-23.6M	—	—	—	—	—

Get alerted when INMB's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Inmune Bio, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of INMB

VANGUARD CAPITAL MANAGEMENT LLC
$1.2M706,424 sh
AQR CAPITAL MANAGEMENT LLC
$1.1M662,218 sh
BlackRock, Inc.
$507.9K311,613 sh
RAYMOND JAMES FINANCIAL INC
$347.2K212,995 sh
GEODE CAPITAL MANAGEMENT, LLC
$310.3K190,215 sh
GOLDMAN SACHS GROUP INC
$301.9K185,245 sh
MILLENNIUM MANAGEMENT LLC
$260.1K159,559 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$258.3K158,452 sh
JANE STREET GROUP, LLC
$218.8K134,232 sh
UBS Group AG
$180.0K110,413 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$1.2M	706,424
AQR CAPITAL MANAGEMENT LLC	$1.1M	662,218
BlackRock, Inc.	$507.9K	311,613
RAYMOND JAMES FINANCIAL INC	$347.2K	212,995
GEODE CAPITAL MANAGEMENT, LLC	$310.3K	190,215
GOLDMAN SACHS GROUP INC	$301.9K	185,245
MILLENNIUM MANAGEMENT LLC	$260.1K	159,559
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$258.3K	158,452
JANE STREET GROUP, LLC	$218.8K	134,232
UBS Group AG	$180.0K	110,413

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put INMB on your watchlist

Track score changes the day Inmune Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is INMB a good stock to buy?

13F Pro's AI-powered analysis of Inmune Bio, Inc. (INMB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INMB are available on the INMB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. INMB is classified as a small company.

Which hedge funds own INMB?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INMB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Inmune Bio, Inc.'s investment landscape.